Despite its popularity in the food and chemical industries, continuous manufacturing in pharmaceutical tablet production has not been well adopted. However, there are diverse advantages of this method. Here, GEA assess the specific benefits
Oral solid dosage forms are still the preferred method of delivery for the pharma industry but what challenges are encountered and how does the industry solve these potential problems?
In this article, Frances Salisbury (partner) and Adam Gregory (associate) — European Patent Attorneys in the Life Sciences team at Mewburn Ellis — discuss innovation and IP of CAR-T therapies in more detail.
If you are considering a quick winter getaway or some last minute sunshine over the festive period, make sure you check your meds or you may get more than you bargain for…
With the industry experiencing dramatic change, from regulatory changes to investments in capacity and the uncertainty of the political landscape, we asked several industry heads to review the opportunities, challenges and trends of 2017.
Oral solid dosage is still the preferred method of drug delivery, however, the patient’s experience when taking medication can mean they adhere to the regimen or not. Here, Dr Brian Wilson and Dr Graeme MacLeod from SPI Pharma look at the challenges
The Association of the British Pharmaceutical Industry (ABPI) has released research showing that the amount of capital invested alongside corporate venture capital (CVC) in UK biotech increased six-fold between 2010 and 2015.
Results from a major survey have demonstrated that manufacturers in the UK are experiencing improved global demand, from European markets in particular, despite the current political uncertainty.
STA Pharmaceutical has reported rapid growth in companies intending to market their products in China using it as a partner following the CFDA announcement of the Market Authorization Holder (MAH) pilot programme last year
The RSA Group, has published a new study analysing the performance of biotechnology boards, CEOs and chairs from both Europe and the US, from an investor viewpoint, demonstrating that European companies are outperforming US ones
Research from the Fraser of Allander Institute (FAI), mapping out the economic contribution of Scotland’s pharmaceutical sector, has been released by the Association of the British Pharmaceutical Industry (ABPI) Scotland.
Today (Monday 27 November) marks the original deadline date for the DSCSA. While the FDA has delayed its enforcement of compliance with these serialisation requirements by a year, pharma is still required to legally comply. Industry tells us more…
